Cargando…

Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population

INTRODUCTION: The aim of this study was to describe factors associated with initiating a biologic as monotherapy vs in combination with a conventional disease-modifying antirheumatic drug (DMARD) in biologic-naive patients with rheumatoid arthritis (RA) enrolled in the Corrona registry. METHODS: Fir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pappas, Dimitrios A., Reed, George W., Saunders, Katherine, John, Ani, Shewade, Ashwini, Greenberg, Jeffrey D., Kremer, Joel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883255/ https://www.ncbi.nlm.nih.gov/pubmed/27747494 http://dx.doi.org/10.1007/s40744-015-0008-9

Ejemplares similares

Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry
por: Mease, Philip J, et al.
Publicado: (2015)

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2015)

“Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients”
por: Pappas, Dimitrios A, et al.
Publicado: (2014)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
por: Benson, Rosalind, et al.
Publicado: (2020)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2015)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2017)

A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis
por: Cappelli, Laura C., et al.
Publicado: (2023)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2017)

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis
por: Reed, George W., et al.
Publicado: (2017)

Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis
por: Lillegraven, Siri, et al.
Publicado: (2019)

Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2017)

Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry
por: Sebba, Anthony, et al.
Publicado: (2023)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Cluster‐Randomized Trial of a Behavioral Intervention to Incorporate a Treat‐to‐Target Approach to Care of US Patients With Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
por: Pappas, Dimitrios A, et al.
Publicado: (2021)

Malignancy validation in a United States registry of rheumatoid arthritis patients
por: Fisher, Mark C, et al.
Publicado: (2012)

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
por: Kremer, Joel M., et al.
Publicado: (2021)

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
por: Harrold, Leslie R., et al.
Publicado: (2016)

Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice
por: Pappas, Dimitrios A., et al.
Publicado: (2019)

Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
por: Padula, Anthony S., et al.
Publicado: (2022)

The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network
por: Harrold, Leslie R, et al.
Publicado: (2014)

Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2020)

Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic‐Naive Rheumatoid Arthritis Patients
por: Kottak, Nicholas, et al.
Publicado: (2018)

Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice
por: Catay, Erika, et al.
Publicado: (2016)

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Emery, Paul, et al.
Publicado: (2018)

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
por: Winthrop, Kevin L, et al.
Publicado: (2021)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry
por: Harrold, Leslie R., et al.
Publicado: (2018)

Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis
por: Mori, Shunsuke, et al.
Publicado: (2021)

Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
por: Codreanu, Catalin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l5ucc5a2b5cqoa0o8mt7k2dcea